Anticancer Therapies – News and Features

The National Cancer Institute (NCI) has announced major changes to be made in the long-established Clinical Trials Cooperative Group Program that conducts many of the nationwide trials of new cancer therapies.

Digital pathology enables a US-based quantitative IHC provider to partner with a UK-based histopathology laboratory in virtual services in companion diagnostics.

Novel Approach in Cancer Therapy is set to be at the Forefront of Gold-Based Medical Applications.

Quantum Immunologics, Inc. announces the appointment of Dr George E. Peoples, M.D., of Brooke Army Medical Center, San Antonio, TX to QI's Scientific Advisory Board.

Newly discovered sets of genes in cancer cells and normal tissue may find possible new treatments for patients with non-small cell lung cancer.

Researchers have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces the merger of its portfolio company Myotec Therapeutics Ltd. (Myotec) with Hybrid Biosystems Ltd. (Hybrid) to form PsiOxus Therapeutics.

Company’s novel GLP-2 agonist continues to advance in clinical development under licensing agreement.

SymBio Pharmaceuticals Limited announces the launch of TREAKISYM® (SyB L-0501, bendamustine hydrochloride) in Japan for the treatment of refractory/relapsed low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma.

Zealand Pharma announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea.